Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Gracell Biotechnologies (GRCL)

Gracell Biotechnologies Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GRCL
DateTimeSourceHeadlineSymbolCompany
04/03/202417:22Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:GRCLGracell Biotechnologies Inc
28/02/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GRCLGracell Biotechnologies Inc
26/02/202422:28Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:GRCLGracell Biotechnologies Inc
26/02/202422:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GRCLGracell Biotechnologies Inc
26/02/202422:26Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GRCLGracell Biotechnologies Inc
26/02/202422:26Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:GRCLGracell Biotechnologies Inc
22/02/202413:50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
22/02/202413:45GlobeNewswire Inc.Gracell Biotechnologies Acquisition CompletedNASDAQ:GRCLGracell Biotechnologies Inc
20/02/202413:22Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
20/02/202412:45GlobeNewswire Inc.Gracell Biotechnologies Announces Shareholders’ Approval of Merger AgreementNASDAQ:GRCLGracell Biotechnologies Inc
14/02/202413:20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GRCLGracell Biotechnologies Inc
30/01/202411:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
29/01/202412:00GlobeNewswire Inc.Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple MyelomaNASDAQ:GRCLGracell Biotechnologies Inc
17/01/202421:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
08/01/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
08/01/202415:06PR Newswire (US)Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law FirmNASDAQ:GRCLGracell Biotechnologies Inc
26/12/202313:12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
26/12/202311:44Dow Jones NewsGracell ADSs Take Flight Premarket on $1.2 Billion Takeover by AstraZenecaNASDAQ:GRCLGracell Biotechnologies Inc
26/12/202308:05Dow Jones NewsAstraZeneca to Buy Gracell Biotechnologies for $1.2 BillionNASDAQ:GRCLGracell Biotechnologies Inc
26/12/202307:01Business WireAstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseasesNASDAQ:GRCLGracell Biotechnologies Inc
26/12/202307:00GlobeNewswire Inc.Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseasesNASDAQ:GRCLGracell Biotechnologies Inc
22/12/202311:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
21/12/202312:00GlobeNewswire Inc.Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusNASDAQ:GRCLGracell Biotechnologies Inc
18/12/202321:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
12/12/202300:30GlobeNewswire Inc.Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023NASDAQ:GRCLGracell Biotechnologies Inc
29/11/202311:18IH Market NewsAmazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and MoreNASDAQ:GRCLGracell Biotechnologies Inc
28/11/202319:59Dow Jones NewsCabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T DrugsNASDAQ:GRCLGracell Biotechnologies Inc
27/11/202313:00GlobeNewswire Inc.Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusNASDAQ:GRCLGracell Biotechnologies Inc
21/11/202311:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GRCLGracell Biotechnologies Inc
16/11/202313:00GlobeNewswire Inc.Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease SummitNASDAQ:GRCLGracell Biotechnologies Inc
 Showing the most relevant articles for your search:NASDAQ:GRCL